On Oct. 14, 2020, Thermo Fisher Scientific announced plans to develop two new sterile filling lines in Singapore to extend capacity to the Asia-Pacific region for the development and manufacture of therapies and vaccines.

Established with the support of the Singapore Economic Development Board (EDB), the $130 million facility will be operated by Thermo Fisher and have the capability to manufacture pharmaceutical products to meet demand in the region and respond effectively to future health emergencies.